1.Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clinical Microbiology Reviews 2008; 21: 538–582.
2.Garnacho-Montero J, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clinical Infectious Diseases 2003; 36: 1111–1118.
3.Olesen S, Madsen PO. Intravenous administration of sodium colistimethate in urinary tract infections. Current Therapeutic Research, Clinical and Experimental 1967; 9: 283–287.
4.Devlieger H, et al. Acute renal failure due to colistin intoxication. Acta Paediatrica Belgica 1977; 30: 179–181.
5.Tascini C, et al. Evaluation of the activities of two-drug combinations of rifampicin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy 1998; 42: 270–271.
6.Song JY, et al. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy 2007; 60: 317–322.
7.Timurkaynak F, et al. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. International Journal of Antimicrobial Agents 2006; 27: 224–228.
8.Zavascki AP, et al. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. Journal of Antimicrobial Chemotherapy 2007; 60: 1206–1215.
9.Knaus WA, et al. APACHE II: a severity of disease classification system. Critical Care Medicine 1985; 13: 818–829.
10.Vincent JL, et al. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine. Intensive Care Medicine 1996; 22: 707–710.
11.Motaouakkil S, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. Journal of Infection 2006; 53: 274–278.
12.American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia: 2005, 15 February 2005. American Journal of Respiratory and Critical Care Medicine 2005; 171: 388–416.
13.Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 21st informational supplement. Document M100–S21. Wayne, PA: CLSI; 2011.
14.Antibiogram Committee of the French Microbiology Society. Report, 2010. Antibiogram Committee of the French Microbiology Society, Paris, France.
15.Isenberg HD. Clinical Microbiology Procedures Handbook, 2nd edn.Washington, DC: ASM Press, 2004.
16.Durmaz R, et al. The optimization of rapid pulse field electrophoresis for the typing of Acinetobacter baumannii. Escherichia coli and Klebsiella spp. Japanese Journal of Infectious Diseases 2009; 62: 372–377.
17.Rementeria A, et al. Comparative evaluation of three commercial software packages for analysis of DNA polymorphism patterns. Clinical Microbiology and Infection 2001; 7: 331–336.
18.Tenover FC, Arbeit RD, Goering RV. How to select and interpret molecular strain typing methods for epidemiological studies of bacterial infections: a review for healthcare epidemiologists. Molecular typing working group of the society for healthcare epidemiology of America. Infection Control and Hospital Epidemiology 1997; 8: 426–439.
19.Kallel H, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Medicine 2007; 33: 1162–1167.
20.Bassetti M, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. Journal of Antimicrobial Chemotherapy 2008; 61: 417–420.
21.Petrosillo N, et al. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clinical Microbiology and Infection 2005; 11: 682–683.
22.Levin AS, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clinical Infectious Diseases 1999; 28: 1008–1011.
23.Acocella G. Clinical pharmacokinetics of rifampicin. Clinical Pharmacokinetics 1978; 3: 108–127.
24.Loos U, et al. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Wiener klinische Wochenschrift 1985; 63: 1205–1211.
25.Ratjen F, et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy 2006; 57: 306–311.
26.Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clinical Infectious Diseases 2006; 43: S89–94.
27.Lin CC, et al. Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia: experience in a tertiary care hospital in northern Taiwan. Journal of Microbiology, Immunology and Infection 2010; 43: 323–331.
28.Giannouli M, et al. Molecular epidemiology and mechanisms of rifampicin resistance in Acinetobacter baumannii isolates from Italy. International Journal of Antimicrobial Agents 2012; 39: 58–63.
29.Kulah C, et al. Characterisation of carbapenem-resistant Acinetobacter baumannii outbreak strains producing OXA-58 in Turkey. International Journal of Antimicrobial Agents 2010; 36: 114–118.
30.Turkoglu M, et al. Colistin therapy in critically ill patients with chronic renal failure and its effect on development of renal dysfunction. International Journal of Antimicrobial Agents 2012; 39: 142–145.
31.Rios FG, et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. European Respiratory Journal 2007; 30: 307–313.
32.Garonzik SM, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrobial Agents and Chemotherapy 2011; 55: 3284–3294.